Talking Techniques


Molecular therapeutics: how far have we come and what's on the horizon?

Season 2, Ep. 14

Uncover the history of molecular therapeutics, the staggering current applications and developments of these therapeutics and what their future could hold, in this episode of Talking Techniques.

To explore the field of molecular therapeutics and provide an insight into their production, is Aaron Clauson, Product Manager at Zymo research. First, we cover the ins and outs of targeting the therapies and how to select the correct type of molecular therapeutic to begin developing a drug for a specific disease, before looking at some of the setbacks and safety errors that have occurred during the development of molecular therapeutics and how researchers have learned from these tragic events.

Aaron also highlights the vital role of plasmids in almost all molecular therapeutic development, detailing the importance of keeping plasmid solutions and transfections free of endotoxins, revealing key solutions for avoiding these contaminants.

Listen today to get all you need to know about molecular therapeutics, from their inception to their most exciting examples and how we can better communicate their benefits to the public in order to avoid mistrust and confusion - as has occurred during the COVID-19 pandemic.


  • What counts as a molecular therapeutic? 01:45-02:40
  • Well known molecular therapeutics: 02:40-05:00
  • What can molecular therapeutics achieve that synthetic chemicals can’t? 05:00-05:55
  • Targeting molecular therapeutics and picking the right type of therapeutic: 05:55-08:25
  • Selecting the appropriate molecular therapeutic: 08:35-11:00
  • Setbacks and safety concerns in gene therapies: 11:00-15:45
  • Preventing off-target effects in gene therapies: 15:45-17:35
  • Challenges in the development of molecular therapeutics: 17:35-19:05
  • Plasmids in molecular therapeutic development: 19:05-23:55
  • Avoiding endotoxins: 23:55-27:45
  • What fields do you find most exciting? 27:45-28:50
  • Better communication of gene therapies to the public: 28:50-32:00
  • Improving molecular therapeutic development: 32:00-37:10

More Episodes


Target enrichment for NGS: why, how and what's next?

Season 2, Ep. 18
In this episode, supported by Roche, we explore a vital aspect of many next-generation sequencing studies: target enrichment. Here, regions of interest are selectively amplified before sequencing takes place. More specifically we examine some of the new technologies improving this key step and their impact on oncology research. My guest for this episode is Brian Godwin, Director of Reagent and Assay Development at Roche sequencing. Brian reveals the myriad of ways that poor target enrichment can impact a study while highlighting its importance at the foundations of many research efforts. Discover the key limitations of some target enrichment techniques and the new technologies that are improving this step, leading to a new suite of applications in oncology research, where damaged or degraded DNA samples are common.Listen today for an overview of the target enrichment process, the most exciting applications of this technique future potential of this step.Contents:Intro: 00:00-01:30Why conduct target enrichment? 00:40-02:45Established technologies for target enrichment: 02:45-04:10Challenges of working with these technologies: 04:20-06:40The impact of these challenges on sequencing results: 06:40-07:35New technologies to address these challenges: 07:35-09:25Primer extension in PCR and target enrichment: 09:25-11:40Exciting applications of primer extension target enrichment: 11:40-13:25Improving target enrichment in oncology and its impact on the field: 13:25-16:15If you could ask for one thing to enable primer extension target enrichment to make the greatest possible impact on the NGS and oncology communities, what would it be? 16:15-18:00

Producing challenging proteins in the golden age of protein engineering

Season 2, Ep. 17
In this episode, we roam the world of recombinant proteins and their production, discussing the challenges of their production, and recent evolutions in protein engineering that have brought the field into a golden era of innovation.I'm joined by recombinant protein engineering expert Yuning Chen, R&D Manager at Sino Biological, who discusses the key applications of recombinant proteins, the aspects of certain products that make them difficult to produce and how these difficulties can be overcome.Yuning also reveals how the manipulation of antibodies has been essential to multiple aspects of our response to the COVID-19 pandemic.After a review of the recent evolutions in protein engineering, from cell-free systems to automation, Yuning describes his vision for the future of the field and reveals his support for the Terminator-style uprising that he believes could revolutionize it.ContentsThe production of recombinant proteins: 00:48-02:11The key applications of recombinant proteins: 02:11-03:27What makes some proteins difficult to produce? 03:27-04:41Overcoming these challenges:04:40-5:40Manipulating antibodies to take part in multiple aspects of pandemic response: 05:40-08:00The most exciting applications of recombinant proteins: 08:00-09:50Developments in high throughput and automated protein engineering: 09:50-11:00Cell-free protein engineering: 11:00-12:40The benefits of cell-free systems: 12:40-13:40What is next for recombinant protein production? 13:40-16:15The dream of automation for the recombinant protein production: 16:15-18:50

The evolution of PCR: From q to dd and beyond

Season 2, Ep. 16
PCR has evolved rapidly over the last few years, an evolution that has been dramatically accelerated by the COVID-19 pandemic. New technologies and approaches have been brought to the fore and the full range of applications for which this technique can be applied have been highlighted, from diagnostics to basic disease research and immunology.This episode explores this evolution, looking at how challenges presented by the pandemic forced the hand of researchers to think outside the box and build on lesser-known PCR technologies. Here, Eddy van Collenburg, Market Development Specialistat Bio-Rad (CA, USA), provides his insight into how ddPCR rose to prevalence during this time and explains how the technology is being used to enable trade, detect new variants and is being used outside of the pandemic.Discover the key role that ddPCR can play in gene therapy research, liquid biopsies, cancer research, single-cell studies and more, in this fascinating overview of the development of PCR and where the technique can go in the future.Contents:Introduction: 00:00-01:30Why was qPCR established as the gold standard for detection?01:30-03:40Limitations of qPCR during the pandemic: 03:40-05:05New varieties of PCR for faster results: 05:05-05:40New varieties for more accurate results: 05:40-06:45ddPCR working principle and advantages: 06:45-09:00Nonclinical ddPCR applications for COVID-19: 09:00-10:45ddPCR in variant detection: 10:45-12:05ddPCR in gene therapy research: 11:05-12:30Liquid biopsy and cancer research: 12:30-15:20Combining ddPCR with NGS in research: 15:20-16:15What are some of the applications of ddPCR that you find most exciting? 16:15-17:10Applications of ddPCR in single-cell studies: 17:10-21:00Improvements in ddPCR: 21:00-21:45Tips for best practice when using ddPCR: 21:45-22:50What would you ask for to improve ddPCR? 21:50-24:20